Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE5302.008.4 (+0.16 % )
PREV CLOSE (Rs.) 5293.60
OPEN PRICE (Rs.) 5325.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 38288
TODAY'S LOW / HIGH (Rs.)5274.05 5339.75
52 WK LOW / HIGH (Rs.)3613.45 5514.65
NSE5301.45 5.5 (+0.1 % )
PREV CLOSE(Rs.) 5295.95
OPEN PRICE (Rs.) 5318.00
BID PRICE (QTY) 5301.45 (158 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 880165
TODAY'S LOW / HIGH(Rs.) 5275.00 5340.00
52 WK LOW / HIGH (Rs.)3613.85 5512.65

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.47
TTM EPS (Rs.) 142.98
P/E Ratio 37.08
Book Value (Rs.) 979.45
Face Value (Rs.) 5
MCap (Rs. in Mn) 881729.13
Price/Earning (TTM) 27.60
Price/Sales (TTM) 6.91
Price/Book (MRQ) 5.41
PAT Margin (%) 24.79
ROCE (%) 18.58
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
12May05-12-2021$Dr. Reddy's Laboratories enters into voluntary licensing agreement with Lilly Dr. Reddy's Laboratories ent

Dr. Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for the manufacture and commercialization of the drug, baricitinib, in India. The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories has entered into a royalty-free, non-e..
12May05-12-2021$Dr. Reddy's Laboratories launches Ertapenem for Injection Dr. Reddy's Laboratories lau

Dr. Reddy's Laboratories has launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the US Food and Drug Administration (USFDA).

The company’s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton. The INVANZ brand and generic market had US sales of around $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories has launched Ertapenem for Injection,..
12May05-12-2021$Dr Reddys Laboratories informs about press release Dr Reddys Laboratories infor
Dr Reddys Laboratories has informed that it has enclosed a Press Release on ‘Dr. Reddy's Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to Covid-19 Treatment in India.’

The above information is a part of company’s filings submitted to BSE.

Dr Reddys Laboratories has informed that it has enclosed a Pres..
12May05-12-2021$Dr. Reddy's Laboratories inches up on entering into voluntary licensing agreement with Lilly Dr. Reddy's Laboratories inc

Dr. Reddy's Laboratories is currently trading at Rs. 5298.00, up by 4.40 points or 0.08% from its previous closing of Rs. 5293.60 on the BSE.

The scrip opened at Rs. 5325.00 and has touched a high and low of Rs. 5325.00 and Rs. 5276.00 respectively. So far 12097 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 3613.45 on 18-May-2020.

Last one week high and low of the scrip stood at Rs. 5422.00 and Rs. 5132.00 respectively. The current market cap of the company is Rs. 88289.32 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.93% and 17.06% respectively.

Dr. Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for the manufacture and commercialization of the drug, baricitinib, in India. The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories is currently trading at Rs. 5298.00, u..
12May05-12-2021$Dr. Reddy’s Laboratories informs about cessation of director Dr. Reddy’s Laboratories i
Dr. Reddy’s Laboratories has informed that Bharat Narotam Doshi, Independent Director of the Company has ceased to be a Director of the Company with effective from May 10, 2021 on completion of his term as an Independent Director.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddy’s Laboratories has informed that Bharat Narotam Dos..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit443729377
Gross Profit 6179 27758
Operating Profit 836836128
Net Sales 34082118504
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 1679.60 (4.62%)
M.Cap ( in Cr)
1037.66
Ajanta Pharma (BSE)
 2002.95 (3.11%)
M.Cap ( in Cr)
17398.94
Solara Active Pharma (BSE)
 1742.70 (2.80%)
M.Cap ( in Cr)
6280.52
Themis Medicare (BSE)
 465.55 (5.54%)
M.Cap ( in Cr)
440.91
Cadila Healthcare (BSE)
 646.95 (2.74%)
M.Cap ( in Cr)
66231.03
Shareholding Pattern More
PROMOTERS 26.74 %
NON-INSTITUTION 17.06 %
MUTUAL FUNDS/UTI 13.31 %
FI/BANKS/INSURANCE 0.94 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes